Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. develops clinical-stage treatments for rare diseases and diseases with high unmet need, with news centered on anti-infective programs for multi-drug resistant bacterial infections. Updates frequently cover tebipenem HBr, an investigational oral carbapenem antibiotic for complicated urinary tract infections, including pyelonephritis, and its licensed development and commercialization relationship with GSK outside certain Asian territories.
Company announcements also report quarterly and annual operating results, business updates, clinical data presentations, FDA submission activity, portfolio-expansion efforts, cash runway commentary, and equity-compensation grants under Nasdaq rules.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on June 30, 2020, the granting of non-qualified stock options for 40,000 shares to five new employees under its 2019 Inducement Equity Incentive Plan. The options, with an exercise price of $13.53 per share, will vest over four years, with 25% vesting after the first year. This incentive is in accordance with Nasdaq Listing Rule 5635(c)(4) and is aimed at attracting talent in the biopharmaceutical sector focused on treating multi-drug resistant bacterial infections and rare diseases.
Spero Therapeutics (Nasdaq: SPRO) will present a corporate update at the Jefferies 2020 Virtual Healthcare Conference on June 4, 2020, at 9:00 a.m. ET. The presentation will be led by Ankit Mahadevia, M.D., President and CEO. Interested individuals can access the webcast on Spero's website under the 'Events and Presentations' section. Spero is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases, including its lead product candidate, tebipenem HBr, aimed at treating MDR Gram-negative infections.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on June 1, 2020, the grant of stock options totaling 29,500 shares to four new employees under its 2019 Inducement Equity Incentive Plan. The options, with an exercise price of $11.82 per share, vest over four years, incentivizing employee retention. This grant aligns with Nasdaq Listing Rule 5635(c)(4), allowing equity awards to non-employees as a recruitment tool. Spero focuses on treating multi-drug resistant infections and rare diseases, advancing key candidates like tebipenem HBr for MDR infections and SPR720 for a rare disease associated with NTM.
Spero Therapeutics (Nasdaq: SPRO) has completed enrollment in its pivotal Phase 3 ADAPT-PO trial for tebipenem HBr, aimed at treating complicated urinary tract infections (cUTI) in approximately 1,370 patients. Top-line results are expected in Q3 2020. The company also plans to initiate a Phase 2a trial for SPR720, targeting non-tuberculous mycobacterial disease. Financially, Spero reported a Q1 2020 net loss of $23.3 million, significantly higher than the $5.1 million loss in Q1 2019. Total revenue dropped to $1.7 million from $7.7 million in the prior year due to reduced funding and collaboration revenue.
Spero Therapeutics (Nasdaq: SPRO) announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, for tebipenem HBr, targeting complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). This milestone involves over 1,370 subjects and aims to compare an oral regimen of tebipenem HBr against standard intravenous treatment. The company expects to report topline results in Q3 2020, emphasizing the unmet need for effective oral therapies to reduce hospitalizations caused by drug-resistant infections.
Summary not available.